Literature DB >> 12588769

Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice.

Nancy R Webb1, Meredith A Bostrom, Stephen J Szilvassy, Deneys R van der Westhuyzen, Alan Daugherty, Frederick C de Beer.   

Abstract

OBJECTIVE: Transgenic mice expressing human group IIA secretory phospholipase A(2) (group IIA sPLA(2)) spontaneously develop atherosclerotic lesions. The mechanism for this proatherogenic effect is likely multifactorial, because HDL-cholesterol is significantly lower and LDL/VLDL cholesterol is slightly higher in transgenic mice compared with nontransgenic littermates. In the present study, we show for the first time that elicited peritoneal macrophages from transgenic mice express human group IIA sPLA(2). This study tested whether macrophage-expressed sPLA(2) contributes to atherogenesis. METHODS AND
RESULTS: Bone marrow cells from either sPLA(2) transgenic mice or control C57BL/6 mice were transplanted into LDL receptor-deficient mice. After hematopoietic engraftment, animals were fed a diet enriched with saturated fat and cholesterol for 12 weeks. Despite a lack of effect on serum lipoprotein concentrations, the presence of bone marrow-derived cells expressing human group IIA sPLA(2) resulted in a significant increase in the extent of atherosclerosis in the aortic arch (12.8+/-1.4% versus 7.4+/-0.9%; P<0.005) and aortic sinus (0.3+/-0.03 mm(2) versus 0.2+/-0.04 mm(2); P<0.05).
CONCLUSIONS: Group IIA sPLA(2) can contribute to atherosclerotic lesion development through a mechanism that is independent of systemic lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588769     DOI: 10.1161/01.atv.0000051701.90972.e5

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

1.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

Review 2.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

3.  Thyroid hormone status regulates the expression of secretory phospholipases.

Authors:  Pragya Sharma; Tania Levesque; Eric Boilard; Edwards A Park
Journal:  Biochem Biophys Res Commun       Date:  2014-01-16       Impact factor: 3.575

4.  A new era of secreted phospholipase A₂.

Authors:  Makoto Murakami; Hiroyasu Sato; Yoshimi Miki; Kei Yamamoto; Yoshitaka Taketomi
Journal:  J Lipid Res       Date:  2015-03-24       Impact factor: 5.922

5.  In utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- mice.

Authors:  Sanjay Srivastava; Stanley E D'Souza; Utpal Sen; J Christopher States
Journal:  Reprod Toxicol       Date:  2007-01-25       Impact factor: 3.143

Review 6.  Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.

Authors:  Robert S Rosenson; Michael H Gelb
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 7.  Role of secretory phospholipases in atherogenesis.

Authors:  Ann-Cathrine Jönsson-Rylander; Sofia Lundin; Birgitta Rosengren; Camilla Pettersson; Eva Hurt-Camejo
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

8.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

9.  Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.

Authors:  Markus van der Giet; Markus Tölle; Domenico Pratico; Volkmar Lufft; Mirjam Schuchardt; Matthias P Hörl; Walter Zidek; Uwe J F Tietge
Journal:  J Mol Med (Berl)       Date:  2009-10-02       Impact factor: 4.599

10.  Secretory PLA2 inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells.

Authors:  K Sonoki; M Iwase; N Sasaki; S Ohdo; S Higuchi; Y Takata; M Iida
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.